Fradet Y, Friede J, Guertin B, Leclerc J, Dufour C, Caron C
Hotel-Dieu de Québec, Canada.
J Urol. 1992 Aug;148(2 Pt 1):418-22. doi: 10.1016/s0022-5347(17)36620-x.
The tumor targeting potential of two monoclonal antibodies (mAbs) reacting with growth-regulated surface glycoproteins of human bladder cancer was investigated. The mAb T16 reacts more intensely with stationary cells while the mAb T43 is preferentially reactive with exponentially growing cells. The test target was T24 human bladder cancer cells grown subcutaneously in 30 nude mice. Controls for tumor specificity were human lung cancer cells grown on the contralateral side. Purified mAb's T16 and T43, and Om5, a non-reactive control, were radiolabeled with 131-Iodine and injected intravenously in doses ranging from 50 to 300 microCi in tumor-bearing animals. Consistent images of the bladder cancer xenografts were obtained at 48 and 72 hours with tumors as small as 0.1 gm. High resolution tumor images were obtained only with the reactive antibodies and according to their in vitro specificity. These results demonstrate that the two mAbs T16 and T43 can specifically and sensitively localize human bladder cancer cells in vivo.
研究了两种与人类膀胱癌生长调节表面糖蛋白反应的单克隆抗体(mAb)的肿瘤靶向潜力。单克隆抗体T16与静止细胞反应更强烈,而单克隆抗体T43优先与指数生长的细胞反应。测试靶点是在30只裸鼠皮下生长的T24人膀胱癌细胞。肿瘤特异性的对照是在对侧生长的人肺癌细胞。将纯化的单克隆抗体T16、T43和非反应性对照Om5用131碘进行放射性标记,并以50至300微居里的剂量静脉注射到荷瘤动物体内。在48小时和72小时时,对于小至0.1克的肿瘤,获得了膀胱癌异种移植瘤的一致图像。仅使用反应性抗体并根据其体外特异性获得了高分辨率肿瘤图像。这些结果表明,两种单克隆抗体T16和T43可以在体内特异性且灵敏地定位人膀胱癌细胞。